60. Meningococcus B - A Reverse Vaccinology Approach to Vaccine Development
Session: Symposium: Vaccines for a Global Community: Meningococcus A and B, Cholera, and Malaria
Thursday, October 20, 2011: 1:00 PM
Room: 205ABC

Rino Rappuoli, MD, Novartis Vaccines, Siena, Italy

Rino Rappuoli is Global Head of Vaccines Research at Novartis Vaccines and Diagnostics, based in Siena, Italy. He earned his PhD in Biological Sciences at the University of Siena and has served as a visiting scientist at Rockefeller University in New York and Harvard Medical School in Boston. He was elected to the US National Academy of Sciences (NAS), the European Molecular Biology Organization (EMBO) and was awarded the Gold Medal by the Italian President for contributions to public healthcare in 2005. In 2009, he received the Albert B. Sabin Gold Medal for his work in the field of reverse vaccinology and in 2010 the Lifetime Achievement Award from the Institute of Human Virology in Maryland. He has published more than 500 works in peer-reviewed journals. He introduced several novel scientific concepts: genetic detoxification, 1987; cellular microbiology, 1996; reverse vaccinology, 2000; and pangenome, 2005. Several molecules he worked with became part of licensed vaccines. He characterized a molecule, CRM197, that today is the most widely used carrier for vaccines against H. influenzae, N. meningitidis and pneumococcus vaccines, and is used multiple times to vaccinate most children of the globe. Then he developed a vaccine against pertussis by engineering B. pertussis to produce a non toxic pertussis toxin antigen. This was the first rationally designed molecule approved for human use. Later he developed the first conjugate vaccine against meningococcus C that eliminated the disease in the UK in 2000. He pioneered the use of genomic information for vaccine development (reverse vaccinology). The first genome-derived vaccine against meningococcus B is now in Phase III clinical trials, several others are in earlier stages of development. Finally, in 1997 he obtained the regulatory approval for MF59, the first vaccine adjuvant approved for human use after the approval of aluminium salts in the 1920s. MF59 is now being used in many other experimental vaccines, the most advanced of which is a vaccine against pandemic influenza.

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.